G. Gerken
Epidemiology · 2000–2019
A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Epidemiology — 44 citations into it
Whom G. Gerken trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- G. Hotamışlıgil (in Epidemiology)
Papers from G. Gerken's perspective
Ordered by how strongly the researchers G. Gerken trusts endorse each paper. Same corpus, a different order for every researcher.
- Autophagy regulates lipid metabolism (Nature)
- Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. (Gastroenterology)
- Inflammation and metabolic disorders (Nature)
- The natural history of nonalcoholic fatty liver disease: a population-based cohort study. (Gastroenterology)
- Enzymes of triacylglycerol synthesis and their regulation. (Progress in lipid research)
- Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. (Journal of Clinical Investigation)
- GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. (Journal of Clinical Investigation)
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites (Hepatology)
- Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway
- Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis (Hepatology)
Their papers
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) — 1,383 citations
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (2012) — 790 citations
- The interaction of hepatic lipid and glucose metabolism in liver diseases. (2012) — 918 citations
- Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. (2005) — 1,195 citations
- Local control of the immune response in the liver (2000) — 617 citations